AIM by Synergyne ART Analytics

What AIM by Synergyne ART Analytics does

AIM by Synergyne ART Analytics is a Canadian medical-technology company headquartered in Saskatoon, Saskatchewan, that developed the AIM platform—an AI-powered, non-invasive endometrial receptivity test for the IVF (in vitro fertilization) market. The product uses proprietary machine learning and computer vision to analyze 2D and 3D ultrasound images of the uterine lining and generate cycle-specific receptivity scores that are not detectable through routine clinical observation or standard biopsy-based methods like ERA (Endometrial Receptivity Analysis). AIM evolved from the company's predecessor technology, Matris™, which rests on more than 25 years of clinical investigation by CSO Dr. Roger Pierson and is supported by over 700 published works, 6 patents, and more than 40 copyrighted computer programs in image analysis and tissue characterization. Additional product offerings include the NEQsi (Numeric Embryo Quality Scoring Index) calculator, which converts standard Gardner embryo grades into numerical values on a linear scale.

The company operates a B2B subscription-style diagnostic services model, entering into negotiated service agreements with fertility clinics that upload ultrasound images through a secure clinic portal and receive receptivity reports (typically within 24-48 hours). AIM is positioned as the only non-invasive, intracycle test on the market, enabling embryo transfer decisions in the actual treatment cycle without requiring a biopsy or mock cycle. The company is a subsidiary of Synergyne Imaging Technology Inc. and is backed by Riverside Ventures (Boot family office) and HoMu Health Ventures, with strategic operating partnerships spanning HoMu Health Ventures (Spain), Cybera's Applied Data Science Lab (AI/ML integration), Boston IVF (US clinical validation), and TRIO Fertility (Canadian clinical collaborator since 2018).

AIM's commercial footprint spans North America, Latin America, and Europe, with active geographic expansion underway into Latin America via the HoMu partnership. The company has reported that clinics using AIM have achieved up to 20% improvement in IVF pregnancy success rates based on clinical data from TRIO Fertility since 2018. Compliance footprint includes PIPEDA, HIPA (Saskatchewan), HIA (Alberta), and PHIPA (Ontario) for personal health information protection, with data stored in Canada and separate secure servers for U.S. patient data.

Name

AIM by Synergyne ART Analytics

Legal name

Synergyne ART Analytics Inc.

Website

https://aimfertility.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

AIM by Synergyne ART Analytics is a Canadian medtech company that developed AIM, an AI-powered non-invasive endometrial receptivity test using computer vision on 2D/3D ultrasound images to guide IVF embryo transfer timing. It sells recurring diagnostic services to fertility clinics in North America, Latin America, and Europe.

Ownership category

akta.pro rank

Product category

AI Fertility Diagnostics

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

• AI fertility diagnostics
• Endometrial receptivity testing
• Ultrasound image analytics
• IVF clinical decision support
• Computer vision healthcare

Headquarters

HQ city

Saskatoon

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Diagnostic Testing Services: AIM provides diagnostic services to fertility clinics by analyzing uploaded ultrasound images and delivering endometrial receptivity scores and reports via a secure clinic portal. Clinics enter into service agreements to access the AIM platform and receive receptivity reports for their patients. Results are typically available within 24-48 hours of image upload. The company operates its business and stores data in Canada, serving clients worldwide.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

AIM by Synergyne ART Analytics provides an AI-powered, non-invasive endometrial receptivity test delivered to fertility clinics through a secure clinic portal. Clinics upload specialized 2D and 3D ultrasound images, and AIM returns a cycle-specific receptivity score within 24–48 hours to guide embryo transfer timing and hormone protocol decisions. The offering is anchored by the Matris™ technology platform, complemented by the free NEQsi calculator that converts Gardner embryo grades to standardized numeric values.

Product overview

AIM by Synergyne ART Analytics offers a unified product portfolio centered on AI-powered endometrial receptivity testing for fertility clinics. The flagship product is AIM, a non-invasive endometrial receptivity test that uses machine learning and computer vision to analyze ultrasound images and generate receptivity scores. AIM evolved from Matris™, the predecessor technology with 30+ years of scientific development. The portfolio also includes the NEQsi Calculator, a complementary tool that converts Gardner embryo grades to numeric scores. These products work together to support fertility clinics in optimizing embryo transfer timing and improving IVF outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• Matris™: Non-invasive endometrial receptivity test using ultrasound image analysis, predecessor to AIM technology.
• NEQsi

Products and services

• AIM Endometrial Receptivity Test AI-powered non-invasive endometrial receptivity test that uses machine learning and computer vision to analyze 2D and 3D ultrasound images and generate cycle-specific receptivity scores, helping fertility clinics determine optimal embryo transfer timing and personalize IVF protocols.
• Matris™ Endometrial Receptivity Test Proprietary non-invasive diagnostic tool that assesses endometrial receptivity prior to embryo transfer by analyzing ultrasound images; predecessor technology to AIM, built on over 30 years of women's health research.
• NEQsi Calculator Free online calculator that converts standard Gardner embryo grades into single numerical values on a consistent linear scale, supporting embryo quality assessment for fertility clinicians and patients.

Quantifiable outcome

• Up to 20% improvement in IVF pregnancy rates
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core.

• Cybera (Applied Data Science Lab)coreTechnology or Integration · 11 July 2024Synergyne ART Analytics Inc. and Cybera's Applied Data Science Lab collaborated to integrate AI/ML into the Matris test. Cybera contributed a team of technology scientists to analyze proprietary data and internal algorithms. The collaboration enhanced efficiency, scalability, and market readiness of the technology, with outcomes including increased scoring efficiency, accelerated commercialization, enhanced appeal to investors, and improved operational scalability through automation. The partnership positions Matris/AIM for rapid expansion into the Latin American market.
• HoMu Health VenturescoreStrategic or Co-development Partner · 12 June 2024HoMu Health Ventures (Barcelona, Spain) entered into an official investment and operating partnership with Synergyne ART Analytics Inc., moving from a prior MOU. The partnership brings scientific expertise, clinic relationships, and proven commercialization track record in advanced reproductive technologies. Co-founders Dr. Santiago Munne and Dr. José Horcajadas will be involved in Synergyne's operations. HoMu's investment in Matris/AIM is based on its advanced ultrasound technology and proven clinical track record, aimed at accelerating global commercialization.
• Cybera (Initial Collaboration)coreTechnology or Integration · 1 May 2023Initial collaboration between Synergyne ART Analytics Inc. and Cybera's Applied Data Science Lab began May 1, 2023, with a team of highly trained technology scientists collaborating closely to integrate AI/ML into Matris. The project aimed to analyze years of proprietary data and internal algorithms to enhance the technology for improved patient outcomes and global marketability.
• HoMu Health Ventures (MOU)coreStrategic or Co-development Partner · 7 March 2023Synergyne ART Analytics Inc. (a subsidiary of Synergyne Imaging Technology Inc.) entered into a Memorandum of Understanding with Barcelona-based HoMu Health Ventures for a co-investment to advance the final development of Matris—the only intracycle, non-invasive diagnostic test to determine endometrial receptivity at the time of embryo transfer.
• Boston IVFcoreStrategic or Co-development Partner · 4 April 2022Boston IVF, a world-leading US fertility clinic and foremost research hub, partnered with Synergyne to validate the improvement in IVF success rates achieved in Canada. Beginning in spring 2022, Boston IVF implemented the Matris tool to authenticate the research in the United States as the final step before full automation. CEO David Stern expressed excitement about being at the forefront of the technology.
• TRIO FertilitycoreStrategic or Co-development Partner · 1 January 2018Toronto-based TRIO Fertility has been a clinical collaborator since 2018, serving as an early adopter of Matris. Together with Synergyne, TRIO gathered and analyzed exhaustive data proving the efficacy of the tool, with results showing up to 20% improvement in IVF pregnancy rates. TRIO's CEO Nicole Condon noted that implementing Matris contributed to TRIO maintaining some of the highest pregnancy success rates in Canada.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Genea Biomedx: Develops ART technology platforms including Geri time-lapse embryo incubators and Gems culture media. Comparable as an AI-adjacent ART technology vendor serving fertility clinics with proprietary decision-support tools.
• Igenomix (Vitrolife): Provider of the ERA (Endometrial Receptivity Analysis) test, the dominant biopsy-based endometrial receptivity diagnostic that AIM directly challenges with a non-invasive AI alternative. Acquired by Vitrolife in 2021, giving it the incumbent scale, salesforce, and clinical footprint AIM must displace.

Others

• Progyny: US fertility benefits management company covering IVF cycles through employer-sponsored plans. Comparable as an adjacent ecosystem player that influences clinic purchasing decisions and patient access to fertility diagnostics like AIM.

Broad incumbents

• Vitrolife: Global IVF/ART consumables and media company that acquired Igenomix. Operates across the IVF workflow with media, culture systems, and now receptivity testing, making it both a potential competitor and a partner/channel for AIM.
• CooperSurgical: Established women's health and fertility diagnostics/medical device company offering ART lab consumables, PGT, and clinic tools. Comparable as a broader incumbent that could bundle an endometrial receptivity solution into its portfolio.
• Hamilton Thorne: Provider of precision instruments, laser systems, and software for the ART/IVF market, including CASA sperm analysis and clinic automation. Comparable as a broader incumbent serving IVF clinics with technology tools.

Emerging players

• Celmatix: Fertility biotech focused on ovarian biology and precision reproductive medicine, with a diagnostic and drug pipeline targeting IVF success. Comparable as a science-led emerging player addressing IVF outcomes via novel biology and data.
• TMRW Life Sciences: AI-enabled automated cryo-storage and specimen management for IVF clinics. Comparable as a venture-backed emerging player bringing software and automation to traditional IVF lab workflows.

Regional players

• Ovation Fertility: US-based network of fertility clinics and labs providing ART services including diagnostics and embryology. Comparable as a clinical counterpart that both consumes endometrial receptivity diagnostics and shapes adoption standards.
• Eugin Group (IVI-RMA): One of the world's largest IVF clinic networks (Europe and Americas), with internal R&D and clinical operations. Comparable as a large clinic network that represents both a major potential customer channel and a regional rollout anchor for AIM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aimfertility

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIM by Synergyne ART Analytics